- Amneal Reports First Quarter 2024 Financial Results
- Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
- Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
- Amneal to Report First Quarter 2024 Results on May 3, 2024
- Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
- Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
- Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
- Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
- Amneal to Participate at Upcoming Investor Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.25 |
---|---|
High | 6.78 |
Low | 5.81 |
Bid | 6.72 |
Offer | 6.73 |
Previous close | 6.21 |
Average volume | 1.93m |
---|---|
Shares outstanding | 308.55m |
Free float | 124.10m |
P/E (TTM) | -- |
Market cap | 1.92bn USD |
EPS (TTM) | -0.3116 USD |
Data delayed at least 15 minutes, as of May 03 2024 16:20 BST.
More ▼